Fosamax and Osteonecrosis of the Jaw: Understanding Causation and Risk

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Specialized Exposure Concerns

For decades, general health and science communication has served as the primary conduit for public understanding of medical conditions and therapeutic options. This legacy framework, rooted in accessible patient education and broad clinical overviews, has effectively disseminated foundational knowledge about bone health, metabolic disorders, and the medications used to manage them. Within this context, audiences have become familiar with the role of bisphosphonates and other antiresorptive therapies in treating osteoporosis, as well as the importance of maintaining skeletal integrity across the lifespan. As this informational landscape matures, a natural progression emerges from generalized health awareness toward more specialized considerations. The transition from broad clinical education to occupational exposure concern requires a shift in focus—from the patient as a recipient of therapy to the professional or individual who may encounter these substances in a controlled environment. In mass production settings, where pharmaceuticals are manufactured, handled, or processed, the potential for unintended exposure introduces a distinct set of considerations. This pivot acknowledges that the same compounds discussed in patient-facing health literature may present different risk profiles when encountered repeatedly in occupational contexts. The following discussion examines how this shift reframes the conversation around exposure, moving from therapeutic benefit to workplace safety without altering the fundamental scientific understanding of the agents involved.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on the legacy of general health education, this section focuses specifically on Fosamax (alendronate), a bisphosphonate medication prescribed for the treatment and prevention of osteoporosis. A known adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, nonviable bone in the maxillofacial region that does not heal within eight weeks after identification. The clinical presentation and diagnosis of ONJ typically involve the presence of exposed bone in the jaw, often accompanied by pain, swelling, infection, or delayed healing after dental procedures. The condition can occur spontaneously but is generally associated with tooth extraction or local infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The pharmacology of Fosamax involves inhibition of osteoclast-mediated bone resorption, which reduces bone turnover. While this mechanism is beneficial for increasing bone density in osteoporosis, it can also impair the normal remodeling and repair processes in the jawbone. Mechanistic pathways linking Fosamax to ONJ include the suppression of bone turnover, which may lead to the accumulation of microdamage and reduced ability to heal after minor trauma, such as dental extractions. Histomorphologic analyses have shown that bisphosphonate-treated bone can exhibit nonvital bone with empty osteocytic lacunae, surrounded by amorphous material and inflammatory infiltrate, indicating impaired bone viability and healing (https://pubmed.ncbi.nlm.nih.gov/41758628/). Multiscale characterization of jawbone tissue has provided information that helps understand jawbone-specific responses to bisphosphonate-related osteonecrosis (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Risk Factors and Clinical Evidence for ONJ

Risk factors for developing ONJ while taking Fosamax include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures. The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific warning under section 5.4 "Osteonecrosis of the Jaw." This warning states that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and outlines known risk factors. The warning also notes that the time to onset of symptoms can vary from one day to several months after starting the drug, and that most patients had relief of symptoms after stopping the medication. However, a subset of patients experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Causation and Management of ONJ

Causation-related considerations for affected patients involve establishing a temporal relationship between Fosamax exposure and the development of ONJ. The timeline between exposure and documented harm can vary widely, with symptoms appearing as early as one day or as late as several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients who develop ONJ, the condition is generally managed by discontinuing the bisphosphonate, addressing any local infection, and providing supportive care such as oral rinses and pain management. In severe cases, surgical debridement may be necessary. It is important to note that the presence of adjunctive treatments, such as leukocyte- and platelet-rich fibrin (L-PRF), did not prevent the occurrence of ONJ in experimental studies (https://pubmed.ncbi.nlm.nih.gov/41758628/). The occurrence of ONJ is not limited to human patients; a retrospective case series documented bisphosphonate-related ONJ in 20 cats, highlighting that this condition is a recognized entity in veterinary medicine as well, though rare (https://pubmed.ncbi.nlm.nih.gov/39247125/). This underscores the biological plausibility of bisphosphonate-induced ONJ across species. In summary, Fosamax is associated with an increased risk of ONJ, particularly in patients with additional risk factors such as invasive dental procedures or poor oral hygiene. The prescribing information includes warnings about this risk, and patients should be counseled on maintaining good oral hygiene and undergoing dental evaluations before starting bisphosphonate therapy. For those who develop ONJ, discontinuation of the drug and appropriate dental care are recommended.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is osteonecrosis of the jaw (ONJ) and how is it related to Fosamax?

Osteonecrosis of the jaw (ONJ) is a condition where exposed, nonviable bone in the jaw fails to heal within eight weeks. It is a known adverse effect of bisphosphonates like Fosamax (alendronate). The mechanism involves suppression of bone turnover, impairing repair after minor trauma such as dental extractions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders like periodontal disease. Longer duration of bisphosphonate use may increase risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How is ONJ diagnosed and managed in patients taking Fosamax?

Diagnosis is based on clinical presentation of exposed jawbone for more than eight weeks. Management includes discontinuing the bisphosphonate, addressing infection, supportive care (oral rinses, pain management), and possibly surgical debridement. Discontinuation before invasive dental procedures may reduce risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.